Rewiring Brain Energy Regulation in Alzheimer’s Disease
This scientific overview examines recent research suggesting that GLP-1 receptor agonists, a class of medications already used for diabetes and obesity, show promise in treating Alzheimer’s disease. The article highlights a study indicating these agonists can reduce amyloid plaques and improve symptoms in mice by activating the AMPK signaling pathway. This activation appears to influence neuronal amyloid-beta metabolism and boost microglial cells’ ability to […]
GLP-1 RAs Enhance AMPK Signaling in Alzheimer’s Disease
Scientific paper explores the potential therapeutic benefits of GLP-1 receptor agonists (GLP-1RAs) for Alzheimer’s disease (AD), building on the known link between type 2 diabetes and increased AD risk. The research indicates that GLP-1 levels are lower in AD, correlating negatively with amyloid-beta (Aβ) levels in patients. Through experiments in transgenic mice and cell lines, the authors […]
FDA halts sale of off-brand Ozempic and other GLP-1 drugs
A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.
GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks – Reuters
GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks Reuters
STAT+: In the war for GLP-1 patients, Novo Nordisk leans on telehealth
Eli Lilly and Novo Nordisk have waged war on telehealth companies marketing compounded versions of their blockbuster diabetes and obesity medications. With shortages of the branded drugs declared over, and the window for compounding copies closed, though, some virtual care companies are emerging as unlikely allies. In the push to get compounded GLP-1 users on […]
Is VKTX Big Pharma’s ticket to the Ozempic arms race?
Is Viking Therapeutics (VKTX) the biotech equivalent of a snack everyone’s eyeing at the pharma party? With its GLP-1/GIP obesity drug VK2735 and an oral version heating up the pipeline, I could see it being the kind of assets Big Pharma drools over. But, I am not certain we will actually see the mergers and […]
Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs
The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. A healthcare team discussing strategies for patient advocacy programs. Beginning in the second half of 2025, the program targets businesses that do […]
Danone takes cues from pharma marketing as GLP-1 changes American appetites
Food and beverage brands are introducing new products that aim to address the questions raised by consumer usage of GLP-1 weight-loss drugs like Mounjaro and Wegovy. At the same time, they’re beginning to borrow from the pharmaceutical and healthcare industry in their media choices. Danone is experimenting with “patient portal” digital out-of-home investments alongside a […]
Study Links GLP-1 Drugs to Lower Cancer Risk
(MedPage Today) — CHICAGO — In patients with type 2 diabetes and obesity, use of GLP-1 receptor agonists was associated with a lower risk of obesity-related cancers and death from any cause, a target trial emulation study found. In a matched…
Miracle drugs don’t come out of nowhere
Robert Huckman and Isaac Kohlberg. Harvard file photos Health Miracle drugs don’t come out of nowhere Healthcare, innovation experts say funding cuts to university labs will slow or stop basic research on which breakthroughs are built Jacob Sweet Harvard Staff Writer May 22, 2025 5 min read The world’s most significant medical therapies often spring […]